抗体偶联药物在肺癌中的研究进展与展望

Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
肺癌创新药物研发
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346152/
https://www.ncbi.nlm.nih.gov/pubmed/35899443
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.22
Descripción
Sumario:Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs.

Ejemplares similares